Form 4: Edwards Lifesciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On April 14, 2025, Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences Corp, exercised employee stock options to acquire 9,500 shares of common stock at a price of $45.2767 per share.
• Simultaneously, Bobo sold 9,500 shares of common stock at a weighted average price of $69.8101 per share, with individual trades ranging from $69.48 to $70.19.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
• Following these transactions, Bobo directly owns 47,206.3707 shares of common stock and indirectly owns 38,817.6991 shares through a 401(k) plan and 135,152 shares by trust.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or prospects.

Positives

• The executive's transactions are being conducted under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and compliant practice.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 plan suggests a planned and compliant approach to these transactions.

Comparison to Industry Standards

• Executive compensation practices, including stock options and trading plans, are common across the medical device industry.
• Companies like Medtronic, Abbott, and Boston Scientific also utilize stock options as part of their executive compensation packages.
• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies to avoid accusations of insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan mitigates concerns about insider trading.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, insider trading, stock options, share sale, Edwards Lifesciences, 10b5-1 plan, executive compensation, beneficial ownership